Prevention and Therapeutic Effects of Fuzheng Huayu Capsule on Liver Fibrosis and Expression of Connective Tissue Growth Factor in Rats

CHEN Han, YANG Bi-wei, YUAN Man. et al

Abstract

To investigate the prevention and therapeutic effects of Fuzheng Huayu Capsule on liver fibrosis in rats and its possible mechanism by regulating the expression of connective tissue growth factor (CTGF).Methods Forty Wistar rats were randomly divided into five groups: the normal group, the preventive group (the preventive experimental group and the preventive control group) and the treatment group (the treatment experimental group and the treatment control group). All the rats, except those in the normal group, were given CCl4 by subcutaneous injection and alcohol by oral adminstration to establish the model of liver fibrosis; meanwhile the rats in normal group were given same amount of olive oil by subcutaneous injection and water by oral administration. The preventive experimental group and control group were treated with Fuzheng Huayu crude drug 0.46 g/kg body mass through stomach irrigation and saline respectively once a day for four weeks during the modeling process. The treatment experimental group and control group were treated with Fuzheng Huayu crude drug 0.46 g/kg body mass through stomach irrigation and saline respectively once a day for four weeks after the modeling process. Blood was collected for the examination of liver function and serum fibrosis marker. HE staining was used to examine the pathological changes in liver tissue. The expression of CTGF was detected by immunohistochemistry. Results Compared with the preventive experimentalgroup, total bilirubin（TB）, alanine aminotransferase（ALT）and hyaluronic acid（HA）in the preventive control group decreased significantly ( P<0.05). Compared with the treatment control group, ALT and laminin（LN in the treatment experimental group decreased significantly ( P<0.01). Compared with the treatment comtrol group, the inflammation and hepatic fibrosis in the treatment experimental group alleviated significantly. The expression of CTGF in the treatment experimental group were significantly lower than that in the treatment control group ( P<0.05). Conclusion Fuzheng Huayu Capsule showed the prevention and therapeutic effects on experimental liver fibrosis. Meanwhile, Fuzheng Huayu Capsule could inhibit the CTGF expression in liver tissue, which may be one of the molecular mechanisms of these effects.

 

Keywords: Hepatic fibrosis, Fuzheng, Huayu, Capsule, CTGF Immunohistochemistry

 

Full Text:

PDF


References


Hayashi H, Sakai T. Animal models for the study of liver fibrosis; new insights from knockout mouse models. Am J Physiol Gastrointest Liver Physiol.2011;300(5) ;G729-G738.

Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol, 2011; 6; 425-456. doi; 10. 1146/ annurev-pathol-011110-130246.

Lee Y, Friedman SL. Fibrosis in the liver acute protection and chronic disease. Prog Mol Biol Transl Sci, 2010; 97 ; 151-200. doi: 10. 1016/B978-0-12-385233-5. 00006-4.

Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology,2008; 134(6); 1655-1669.

Iredale J. Defining therapeutic targets for liver fibrosis; exploiting the biology of inflammation and repair. Pharmacol Res,2008;58(2):129-136.

Deng X. Liang J, Liu Z. et al. Treatment of posthepatitic cirrhosis by Fuzheng Huayu Tablet for Reinforcing Qi and Resolving Stasis. Chin J Integr Med,2013; 19(4);289-296.

Liu P. Fuzheng Huayu Capsule in the treatment of liver fibrosis; clinical evidence and mechanism of action. Chin J Integr Med,2012; 18(5):398-400.

Ferdoushi SL, Paul D, Ghosh CK, et al. Correlation of connective tissue growth factor (CTGF/CCN2) with hepatic fibrosis in chronic hepatitis B. Mymensingh Med J, 2015; 24(3):558-563.

Borkham-Kamphorst E, Weiskirchen R. The PDGF system and its antagonists in liver fibrosis. Cytokine Growth Factor Rev. 2015;()ct 30. pii: S1359-6101 ( 15) 30005-8. doi: 10. 1016/j. cytogfr. 2015. 10. 002.

Su TH. Kao JH, Liu CJ. Molecular mechanism and treatment of viral hepatitis-related liver fibrosis. Int J Mol Sci, 2014; 15(6):10578-10604.

Chen CC, Lau LF. Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol, 2009; 41 (4): 771-783.

Rodgers BD, Roalson EH, Thompson C. Phylogenetic analysis of the insulin-like growth factor binding protein (IGFBP) and IGFBP-related protein gene families. J Gen Comp Endocrinol, 2008;155(1):201-207.

Tache D, Bogdan F. Pisoschi C, et al. Evidence for the involvement of TGF-pl-CTGF axis in liver fibrogenesis secondary to hepatic viral infection. J Morphol Embryol.2011; 52(1 Suppl):409-412.

Wang Q, Usinger W, Nichols B, et al. Cooperative interaction of CTGF and TGF-p in animal models of fibrotic disease. J Fibrogenesis Tissue Repair, 2011; 4 (1): 4. doi: 10. 1186/1755- 1536-4-4.

Gressner OA, Gressner AM. Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases. Liver Int, 2008;28(8):1065-1079.

Kodama T, Takehara T, Hikita H. et al. Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. J Clin Invest, 2011;121(8):3343-3356.


Refbacks

  • There are currently no refbacks.